Research out of Brigham and Women’s Hospital in Boston found heart failure patients who self-identify as black, Latinx or female are less likely to be admitted to the hospital’s cardiology department, suggesting admission bias might be a partial contributor to known racial disparities in HF outcomes.

The combo drug sacubitril/valsartan was associated with early improvements in health status in a study of nearly 4,000 patients with HFrEF.

Metformin use is linked to a lower risk of hospitalization for heart failure in patients with type 2 diabetes, a paper in the Journal of the American Heart Association confirms.

A novel machine learning algorithm improved patient selection for CRT in a study of nearly 1,000 heart failure patients, representing an opportunity to optimize care and spare certain individuals from a pricey procedure that might not benefit them.

Pharmaceutical company AstraZeneca announced Oct. 21 that its drug Farxiga—or dapagliflozin—was approved by the FDA to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes.

Around one in five heart patients in cardiac rehabilitation are depressed, anxious or stressed, according to a new study published in the European Journal of Preventive Cardiology.

Evidence published in BMJ Heart last month supports the idea of an “obesity paradox” in heart failure, further complicating a long-running debate as to whether extra weight can be cardioprotective in patients with established CVD.

A 90-minute communication skills course improved conversations about ICD deactivation and goals of care between clinicians and their patients, according to the recently published results of the WISDOM study.